VEGFA and fibrosarcoma: Being a multikinase inhibitor, sorafenib inhibits cell proliferation as well as angiogenesis by inhibiting rapidly accelerated fibrosarcoma (RAF), vascular endothelial growth factor (VEGF), and platelet-derived growth factor (PDGF) pathways in addition to CSF1R.